Spruce Biosciences BLA filing for rare disease drug on track for 2026
FREE Breaking News Alerts from StreetInsider.com!
StreetInsider.com Top Tickers, 9/21/2026
- AI stocks lift Wall St as oil falls, Treasury yields decline
- Meta AI agent ‘Muse’ triggers massive tech rally as chips and Wall Street soar
- Oil price dips briefly below $100 on Saudi exports, hopes of US-Iran diplomacy
- Paramount, Warner Bros jump on report of settlement progress in merger fight
- Investors may be underpricing how far rate hikes could go, Deutsche says
- Far-left party wins Berlin election, pledging to nationalise housing
- Cybercrime feud erupts on dark web as notorious group claims hijack of rival's website
- Qatar Investment Authority targets $20B partnership with JPMorgan - Bloomberg
- Meta AI agent ‘Muse’ triggers massive tech rally as chips and Wall Street soar
- AMD stock jumps as chip rally builds ahead of summit
Spruce Biosciences Announces Positive Pre-BLA Meetings with FDA and Confirms BLA Submission for TA-ERT on Track for Q4 2026
August 24, 2026 8:00 AM EDTFDA Found Spruce's Chemistry, Manufacturing and Controls (CMC) Comparability Strategies Reasonable to Support the BLA Following Technology Transfer to Leading Global Biologics Manufacturer
Spruce and FDA Aligned on the Overall Content and Format of the Planned BLA, Including Structure of the Integrated Efficacy and Safety Summaries
Spruce Continues to Advance Its Planned Biologics License Application (BLA) on the Accelerated Approval Pathway Based on Reduction of Cerebrospinal Fluid Heparan Sulfate Non-Reducing Ends (CSF HS-NRE)
SOUTH SAN FRANCISCO, Calif.--(BUSINESS WIRE)-- Spruce Biosciences, Inc. (Nasdaq:... More
